Dr. Tiziana Patrizia Cremona has a strong academic and research background in cellular and molecular biology. She completed her undergraduate studies in Cellular and Molecular Biology at the University of Rome Tor Vergata and subsequently earned a Master’s degree in Biology Applied to Biomedical Research from the University of Rome La Sapienza. She then pursued a PhD in Biomedical Sciences at the University of Bern, where her research focused on the development of emphysema induced by cigarette smoke exposure.
In 2017, Dr. Cremona was awarded a prestigious fellowship at Harvard University, T.H. Chan School of Public Health, where she expanded her expertise by studying lung remodeling and experimental models of asthma.
In 2021, she returned to Switzerland and joined the Department for Biomedical Research, where her work concentrated on a rare pulmonary disorder, alpha-1 antitrypsin deficiency. She is currently a senior postdoctoral researcher at the University of Bern within the Department of Chemistry, Biochemistry and Pharmaceutical Sciences. Her current research spans diseases affecting multiple organs, including the colon and uterus, with a particular focus on conditions that are often underrepresented in research and public discourse due to stigma or taboo, such as colitis and endometriosis.
About the BLACKSWAN Foundation
Founded in Switzerland in 2010, the BLACKSWAN Foundation (blackswanfoundation.ch) accelerates research on rare and orphan diseases worldwide. By funding innovative, cross-disciplinary projects across all rare conditions, the Foundation helps uncover solutions that benefit many communities. It also hosts the biennial RE(ACT) Congress, a leading international forum where scientists, clinicians, and patient advocates share breakthroughs and set new directions for the field. Through science, collaboration, and advocacy, the Foundation aims to raise global awareness and give a voice to people often overlooked by traditional health systems. This book is part of that mission—bringing knowledge, hope, and momentum to the urgent fight against rare diseases.
